Oncology Medical Billing Services
Oncology billing fails in two places no other specialty combines: the chemotherapy administration hierarchy and the buy-and-bill drug ledger. A single infusion chair generates a time-based administration code, one or more sequential-infusion add-ons, a J-code for the drug itself paid at Average Sales Price plus a statutory margin, and a wastage attestation on every single-dose vial — and any one of them, coded wrong, converts a five-figure claim into a denial or a clawback. MedPrecision bills oncology as an integrated charge, reconciling the administration codes, the drug units, the wastage modifiers, and the prior authorization on the same claim so the practice is paid for the drug it purchased and the chair time it delivered.
- check_circleFree audit
- check_circleNo contract
- check_circleHIPAA-secure
- check_circleCancel anytime
What do oncology billing services cover?
Oncology billing services manage chemotherapy and infusion administration coding (CPT 96413, 96415, 96417), Part B drug billing under the Average Sales Price + 6% formula, mandatory JW/JZ drug-wastage modifiers on single-dose vials, and payer prior authorization — the four failure points that make oncology the most denial-prone specialty to bill.
- Chemo administration is a strict hierarchy: one initial code (96413) per encounter, then add-ons
- Medicare pays most Part B drugs at ASP + 6% (about ASP + 4.3% after sequestration)
- The JZ modifier has been mandatory on single-dose-vial claims since July 1, 2023
- Prior authorization is the single largest source of oncology treatment delay
Who This Page Is For
Common Billing Friction in Oncology
The chemotherapy administration hierarchy and the single-initial-code rule
Chemotherapy administration is coded as a ranked hierarchy, not a flat list. CPT 96413 reports the initial intravenous infusion of up to one hour of a single or initial substance; 96415 is an add-on reporting each additional hour of that same infusion; 96417 reports each additional sequential infusion of a new drug. Only one initial (96413) may be reported per encounter through a single IV site, and infusion outranks push, which outranks injection. Coders who bill a second initial code, or who miss the sequential-infusion add-on on a multi-drug regimen, either trigger an edit or leave paid units on the table (CMS coverage article 53049).
Buy-and-bill drug economics on the ASP + 6% formula
In the buy-and-bill model the practice purchases the chemotherapy agent, holds it in inventory, administers it, and then bills the payer. Medicare reimburses most physician-administered Part B drugs at 106 percent of Average Sales Price — ASP plus a 6 percent add-on set in statute — which the 2 percent Medicare sequester reduces to an effective rate near ASP + 4.3 percent. Because the practice has already paid for the drug, a single denied or under-paid J-code line is a direct inventory loss, not just deferred revenue.
Mandatory JW/JZ wastage attestation on every single-dose vial
Since July 1, 2023, CMS requires a wastage modifier on every single-dose-container drug claim: JW reports the amount of drug discarded and not administered, and JZ attests that zero drug was wasted. From October 1, 2023, CMS began returning claims for single-dose HCPCS codes as unprocessable when neither modifier is present. Oncology, which runs almost entirely on single-dose vials, is the specialty most exposed to this edit.
Prior authorization as the primary treatment-delay and denial driver
Oncology carries one of the heaviest prior-authorization burdens in medicine. In a 2024 Cancer Care survey of oncology patients, 12 percent reported spending 41 or more hours — a full business week — on a single prior authorization request, and 29 percent spent two to three business days. Every unmanaged authorization is both a care delay and a denial waiting to happen when the drug is administered before approval posts.
Modifier discipline across drug, admin, and same-day E/M lines
An oncology claim frequently stacks a separately identifiable evaluation-and-management visit (modifier 25), a chemotherapy administration line, sequential-infusion add-ons, and a drug J-code with its wastage modifier — each with its own edit logic. Missing modifier 25 bundles the visit into the procedure; a wrong units calculation on the J-code trips Medically Unlikely Edits; a missing sequential-infusion modifier suppresses a payable add-on.
Oncology-Specific Payer Issues We Watch For
Medicare
Issue: Single-dose-vial claims without a JW or JZ modifier are returned as unprocessable (in effect since October 1, 2023), and Part B drug lines pay at ASP + 6% before the 2% sequester — leaving no margin for a units error.
Our approach: We attach the correct wastage modifier and documented discarded units on every single-dose claim, and reconcile billed J-code units to the administered dose before submission.
Commercial (BCBS / UnitedHealthcare / Aetna / Cigna)
Issue: Chemotherapy, immunotherapy, and supportive drugs are gated behind pathway-based prior authorization and site-of-care policies that differ by plan; administering before approval posts converts a covered service into a denial.
Our approach: We secure authorization tied to the exact drug and units, track it against the treatment calendar, and flag any regimen change that voids an existing approval.
All payers
Issue: Missing modifier 25 on a separately identifiable same-day office visit bundles the E/M into the administration; a missed sequential-infusion add-on suppresses a payable line on multi-drug regimens.
Our approach: We audit the administration hierarchy and same-day E/M on every encounter so each payable line is present and correctly modified.
What We Handle
Chemotherapy & infusion administration coding (96413 / 96415 / 96417)
We code the administration hierarchy on every encounter — one initial infusion code, correct each-additional-hour and sequential-infusion add-ons for multi-drug regimens, and the right push-versus-infusion distinction — so the chair time is fully and defensibly captured.
Part B drug (J-code) billing and units reconciliation
We reconcile the administered dose to billed J-code units against the ASP + 6% payment logic and Medically Unlikely Edit caps, so the drug the practice purchased is the drug the payer reimburses — the core of buy-and-bill margin protection.
JW/JZ single-dose-vial wastage modifiers
Every single-dose-container claim carries the correct wastage attestation — JW for discarded drug with the documented wasted units, JZ for zero waste — so claims clear the mandatory edit in place since July 1, 2023 instead of returning as unprocessable.
Prior authorization and payer-specific medical-necessity management
We obtain and track chemotherapy, immunotherapy, and radiation authorizations against each payer's medical-policy and pathway requirements, and align the authorization to the exact drug and units billed so administration and approval never diverge.
Radiation oncology and multi-modality claim coordination
We coordinate medical, radiation, and infusion oncology on one revenue cycle — treatment-planning, delivery, and management coding for radiation alongside medical-oncology drug and administration billing — so a multi-modality patient is billed as one clean record.
Denial appeals and underpayment recovery on high-dollar claims
Because oncology denials carry drug-level dollar amounts, we work every denied and underpaid line to appeal — reconstructing the administration hierarchy, units, and authorization trail that the original claim needed — rather than writing off a five-figure claim.
Free Billing Audit · No obligation
Is your oncology billing leaving money on the table?
We audit your last 90 days of oncology claims for under-coding, modifier errors, and denials — and show you the recoverable dollars at no cost. Written findings in 3–5 business days.
Key Oncology CPT Codes
| CPT Code | Description | Avg. Reimbursement |
|---|---|---|
| 96413 | Chemotherapy administration, IV infusion; up to 1 hour, single or initial substance/drug | $181–227 commercial |
| 96415 | Chemotherapy IV infusion; each additional hour (add-on to 96413) | — |
| 96417 | Chemotherapy IV infusion; each additional sequential infusion of a new drug/substance, up to 1 hour (add-on) | — |
| 96409 | Chemotherapy administration; IV push, single or initial substance/drug | — |
| 96360 | IV infusion, hydration; initial, 31 minutes to 1 hour | — |
| 96375 | Therapeutic/prophylactic/diagnostic injection; each additional sequential IV push of a new drug (add-on) | — |
| 77427 | Radiation treatment management, 5 treatments | — |
| JW / JZ | Drug wastage modifiers — JW = discarded amount; JZ = zero waste (mandatory on single-dose vials since 7/1/2023) | — |
Why General Billing Teams Miss Oncology Issues
General billing staff handle dozens of specialties and rarely develop the depth needed for oncology coding nuances. Here is what gets missed.
Modifier and bundling errors
Specialty-specific modifier rules and CCI edits are frequently overlooked by teams that do not work exclusively in oncology.
Under-coding high-complexity visits
Oncology encounters often qualify for higher-level E/M codes, but generalist billers default to mid-level codes to avoid audit risk.
Missed payer-specific rules
Each payer has unique coverage and documentation requirements for oncology procedures that general teams rarely memorize.
Slow denial turnaround
Without specialty knowledge, appeal letters lack the clinical specificity needed to overturn oncology denials quickly.
Transition Plan
Switching billing partners should not disrupt patient care or cash flow. Our transition plan is designed for zero downtime.
Discovery and Specialty Audit
We review your current oncology billing workflows, denial patterns, and payer mix to build a tailored onboarding plan.
System Integration
We connect to your EHR and practice management system, configure specialty-specific code sets, and validate charge capture workflows.
Parallel Billing Period
We run billing in parallel with your current process for 2-4 weeks to verify accuracy before taking over completely.
Full Transition and Reporting
Once validated, we assume full billing responsibility with monthly reporting dashboards and a dedicated account manager.
Oncology Billing Terms
- Buy-and-bill
- The model in which an oncology practice purchases physician-administered drugs, holds them in inventory, administers them to the patient, and then bills the payer — putting the practice's own capital at risk on every claim.
- ASP + 6%
- The statutory Medicare Part B payment rate for most physician-administered drugs: 106 percent of the drug's Average Sales Price. The 2 percent Medicare sequester reduces the effective add-on to about 4.3 percent.
- JW / JZ modifiers
- Mandatory single-dose-vial wastage modifiers. JW reports drug discarded and not administered; JZ attests zero waste. Required on affected claims since July 1, 2023.
- Sequential infusion
- Administration of a new, different drug through the same IV access after the initial infusion, reported with add-on code 96417 — commonly missed on multi-drug chemotherapy regimens.
Last updated: 2026-07-19
Common Questions
Common questions about oncology billing services.
Request a Specialty Billing Review
See how specialty-specific billing support can improve reimbursement visibility for oncology billing services.
Request Review arrow_forwardWhat CPT codes are used for chemotherapy administration?
Chemotherapy administration uses a hierarchy of CPT codes. 96413 reports the initial IV infusion of up to one hour of a single or initial drug; 96415 is an add-on for each additional hour of that infusion; 96417 reports each additional sequential infusion of a new drug. 96409 covers an IV push rather than an infusion. Only one initial administration code may be billed per encounter through a single IV line, and infusion ranks above push, which ranks above injection.
How does Medicare pay for chemotherapy drugs?
Medicare reimburses most physician-administered Part B chemotherapy drugs at the Average Sales Price plus a 6 percent add-on (106% of ASP), a rate set in statute. The 2 percent Medicare sequester reduces the effective payment to roughly ASP + 4.3 percent. Because oncology practices purchase these drugs up front under the buy-and-bill model, an incorrectly coded or denied drug line is a direct inventory loss.
What are the JW and JZ modifiers in oncology billing?
JW and JZ are drug-wastage modifiers for single-dose containers. JW reports the amount of a single-dose vial that was discarded and not administered; JZ attests that zero drug was wasted. CMS has required one of the two on single-dose-vial claims since July 1, 2023, and began returning claims without them as unprocessable on October 1, 2023. Oncology, which runs almost entirely on single-dose vials, is the specialty most affected.
Why do oncology practices lose revenue on prior authorization?
Prior authorization is oncology's largest source of treatment delay and downstream denial. In a 2024 Cancer Care survey, 12 percent of oncology patients reported spending 41 or more hours on a single prior authorization request and 29 percent spent two to three business days. When a drug is administered before the authorization posts — or when a regimen change voids an existing approval — the high-dollar claim denies. Managing authorization against the exact billed drug and units is what prevents the loss.
Related Services
Related Specialties
Stop losing oncology margin to denials and wastage edits
Get a free review of your chemotherapy administration coding, drug-unit reconciliation, and prior-authorization workflow. We'll show you where oncology revenue is leaking and what it takes to recover it.
- check_circleNo contract
- check_circleNo setup fees
- check_circleReply within 1 business day